Sugammadex transiently suppresses maternal progesterone and estradiol more than neostigmine during C-section
Background
Reversal of neuromuscular blockade during cesarean section requires careful consideration due to the unique endocrine state of parturients. Traditional agents like neostigmine have known effects, but the newer agent sugammadex, a modified γ-cyclodextrin, has a high affinity for aminosteroid neuromuscular blockers. This structural characteristic raises concerns about potential transient interactions with endogenous steroid hormones, which are crucial for maternal physiology and fetal well-being, especially during the peripartum period. Understanding these interactions is vital for optimizing obstetric anesthesia safety and maternal outcomes.
Study Design
This randomized controlled trial enrolled 44 parturients (≥37 weeks) undergoing cesarean section under general anesthesia. Participants received either 2 mg/kg sugammadex or 0.03 mg/kg neostigmine for neuromuscular blockade reversal. Serum concentrations of progesterone, estradiol, aldosterone, cortisol, prolactin, and oxytocin were measured at four time points: preoperatively, at the end of surgery, and at 15 minutes and 4 hours postoperatively. The primary endpoint was the comparison of changes in these maternal steroid and lactation-related hormone levels between the two groups.
Results
Both groups experienced significant postoperative decreases in progesterone and estradiol from preoperative values. However, the sugammadex group showed a greater reduction in these hormones (p<0.05). Aldosterone levels peaked at the end of surgery in both groups, but by 4 hours postoperatively, they were lower than preoperative levels, with a more pronounced decrease observed in the sugammadex group (p<0.001). Cortisol exhibited a temporary postoperative elevation in both groups. Prolactin and oxytocin levels increased in both groups post-surgery, with no significant differences found between the sugammadex and neostigmine arms. All measured hormone levels largely returned to near preoperative values within 4 hours. Importantly, no clinically significant adverse outcomes were associated with these temporary hormonal fluctuations.
The sugammadex group exhibited a greater decrease in progesterone and estradiol levels after surgery compared to preoperative values (p<0.05).
Key Findings
- Sugammadex caused a greater decrease in maternal progesterone levels post-surgery compared to neostigmine (p<0.05).
- Maternal estradiol levels decreased more significantly with sugammadex than with neostigmine (p<0.05).
- Aldosterone levels decreased more substantially in the sugammadex group by 4 hours post-surgery (p<0.001).
- Prolactin and oxytocin levels rose in both groups with no significant intergroup differences.
- All measured hormone levels returned to near preoperative values within 4 hours post-surgery.
Why It Matters
This study provides crucial reassurance for the use of sugammadex in obstetric anesthesia, particularly for cesarean sections. Despite its transient impact on maternal steroid hormones like progesterone and estradiol, these changes are short-lived and do not appear to translate into adverse clinical outcomes or affect lactation-related hormones. Clinicians can confidently use sugammadex for neuromuscular blockade reversal in pregnant patients, knowing that its hormonal effects are temporary and clinically benign. This finding supports sugammadex as a safe alternative to neostigmine in this sensitive population, potentially improving patient safety and recovery profiles without compromising critical maternal endocrine functions or breastfeeding initiation.
sugammadex
neostigmine
cesarean section
maternal hormones
obstetric anesthesia
randomized clinical trial